Mucus plugs are present in more than half of patients with moderate-to-severe COPD and are linked to reduced lung function, more exacerbations, and higher mortality. No approved therapy targets them directly.

The Gothenburg-based company has already shown that MLT-001 can be synthesized at scale. Working with a contract development and manufacturing organization (CDMO), it will now develop a purification process with documented yield, along with a process description and control strategy that can later be transferred to Good Manufacturing Practice (GMP) production.

“Manufacturing is the step that turns a promising molecule into a medicine. With Vinnova’s support, we can build the purification process for MLT-001 and move closer to clinical trials,” says Thaher Pelaseyed, CEO of MucoLife.